ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0728

Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study

Philip Conaghan1, Xavier Chevalier2, Linda Mindeholm3, Ursula Schramm3, Jens Praestgaard3, Abdelkader Seroutou3, Ronenn Roubenoff3 and Matthias Schieker3, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, 3Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland

Meeting: ACR Convergence 2021

Keywords: C-reactive protein (CRP), Inflammation, Interleukins, Nonsteroidal antiinflammatory drugs (NSAIDs), Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Osteoarthritis – Clinical Poster II (0723–0738)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This phase II study investigated the efficacy, safety, and pharmacokinetics of canakinumab, an anti-interleukin-1β antibody, in patients (pts) with knee OA (NCT01160822).

Methods: The study had a single placebo (PBO)-controlled ascending dose period assessing the safety of intra-articular (i.a.) canakinumab, and an 18-week randomized, double-blind, double-dummy PBO and naproxen-controlled period. Pts (N = 136) with symptomatic knee OA (VAS pain ≥40, Kellgren/Lawrence [K/L] grade 2 or 3) were enrolled to receive a single i.a. injection of canakinumab 600 mg or matched PBO at baseline (BL), and naproxen 500 mg twice daily or matched PBO. Co-primary endpoints were change from BL in knee OA pain (VAS 0-100] at Day 4 and in Western Ontario and McMaster OA Index (WOMAC) pain (scale 0-20) at Day 29.

Results: Canakinumab i.a was generally safe and well tolerated and had a short resident time in the joint with an early detection (1 hour) in the circulation after i.a. injection. The co-primary efficacy endpoints were not met. The rapid and clinically significant decreases from BL in VAS pain and WOMAC pain scores were largely comparable between canakinumab, PBO and naproxen (Figure 1A). In a post hoc analysis of pts with BL elevated high sensitive C-reactive protein (hsCRP) levels (≥2 mg/L), canakinumab had a more pronounced inhibitory effect on pain than PBO or naproxen (-2.56 [-5.16; 0.04], P = 0.11; adjusted mean (90% CI) from a mixed-effect model repeated measures [MMRM]) at Day 57. Furthermore, this subpopulation showed a (-1.24 [-3.87; 1.39], P = 0.44) reduction of WOMAC pain at Day 85 compared to PBO or naproxen (Figure 1B).

Conclusion: The effect of canakinumab on pain in a population with knee OA was not different from PBO or naproxen. An effect of canakinumab on pain was observed in a subpopulation with elevated BL hsCRP levels. In addition to the data published previously on the CANTOS study2, these findings underscore the need to identify specific populations of pts with knee OA, who may benefit from anti-inflammatory treatment.

References: 1. Eymard F, Chevalier X. Rev Prat. 2019;69:515-9. 2. Schieker et al, Ann Intern Med. 2020;173:509-15.


Disclosures: P. Conaghan, AbbVie, 2, 6, BMS, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, AstraZeneca, 2, 6; X. Chevalier, Ibsa, 2, 5, 6, Sanofi, 2, Flexion therapics, 1, 2, magpharma, 1; L. Mindeholm, Novartis, 3, 12, Shareholder; U. Schramm, Novartis, 3, 12, Shareholder; J. Praestgaard, Novartis, 3; A. Seroutou, Novartis, 3; R. Roubenoff, Novartis, 3, 11; M. Schieker, Novartis, 3, 11.

To cite this abstract in AMA style:

Conaghan P, Chevalier X, Mindeholm L, Schramm U, Praestgaard J, Seroutou A, Roubenoff R, Schieker M. Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/intra-articular-canakinumab-anti-interleukin-1%ce%b2-for-treatment-of-symptomatic-knee-osteoarthritis-a-randomized-double-blind-placebo-and-naproxen-controlled-phase-ii-study/. Accessed May 15, 2022.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intra-articular-canakinumab-anti-interleukin-1%ce%b2-for-treatment-of-symptomatic-knee-osteoarthritis-a-randomized-double-blind-placebo-and-naproxen-controlled-phase-ii-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.